PT-141 (Bremelanotide)

Bremelanotide, known during its early development as PT-141, is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH), the endogenous hormone that activates the melanocortin receptor family. It is structurally a metabolite of Melanotan II, an earlier synthetic melanocortin agonist developed at the University of Arizona in the 1990s primarily as a sunless tanning agent; bremelanotide is formed when the C-terminal amide of Melanotan II is hydrolyzed to a free carboxylic acid, a change that alters its pharmacological profile enough that Palatin Technologies developed it as a separate clinical candidate. Its clinical history is unusual among the peptides in this queue: it was first tested as an intranasal treatment for male erectile dysfunction under the PT-141 name, that program was discontinued in the mid-2000s after regulators raised concerns about dose-related blood-pressure increases at the doses needed for reliable intranasal efficacy, and the compound was later repositioned, reformulated as a subcutaneous injection, and studied specifically in women with low sexual desire. That repositioned program culminated in FDA approval in June 2019 under the brand name Vyleesi, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, making bremelanotide one of only two FDA-approved medications for this indication and the only approved peptide-based treatment for it.

Bremelanotide is a non-selective agonist across the melanocortin 1, 3, and 4 receptors (MC1R, MC3R, MC4R), without meaningful subtype selectivity. Its desire-enhancing effect is attributed primarily to MC4R activation in hypothalamic regions implicated in sexual motivation, including the medial preoptic area and paraventricular nucleus, based on rodent behavioral pharmacology and, more recently, direct human neuroimaging evidence. Its activity at MC1R, the receptor that governs melanocyte pigment production and that Melanotan II was originally designed to exploit for tanning, is an unavoidable consequence of its non-selective binding profile rather than a therapeutic mechanism, and accounts for the focal skin and gum hyperpigmentation observed with repeated dosing. Its activity at MC3R, a receptor also implicated in energy homeostasis, is thought to underlie a modest, incidentally observed effect on body weight seen in a post hoc trial analysis, though bremelanotide is not developed or approved for that purpose. Unlike phosphodiesterase-5 inhibitors used for erectile dysfunction, which act peripherally on vascular smooth muscle, bremelanotide mechanism is understood to be predominantly central, acting on brain circuits governing desire rather than directly on genital blood flow.

The strongest evidence for bremelanotide comes from two identical, multicenter, randomized, double-blind, placebo-controlled phase 3 trials, the RECONNECT studies, published in Obstetrics and Gynecology in 2019 and enrolling a combined 1,247 premenopausal women diagnosed with hypoactive sexual desire disorder. Self-administered subcutaneous bremelanotide at 1.75 milligrams, taken as needed before anticipated sexual activity, produced statistically significant improvements over placebo in both co-primary endpoints, an increase in Female Sexual Function Index desire-domain score and a reduction in desire-related distress, over a 24-week treatment period. A preceding phase 2b dose-ranging trial and its published responder analysis found a higher proportion of clinically meaningful responders with bremelanotide than placebo, though, as is common in trials of sexual desire, a substantial minority of placebo-treated women also improved, meaning the absolute treatment effect attributable to the drug itself, while statistically real and the basis for approval, is more modest than the raw within-group improvement figures might suggest on their own. A 2022 human functional MRI study added direct neuroimaging evidence that a single bremelanotide dose alters activity in brain regions tied to sexual arousal processing, corroborating the proposed central mechanism with human, rather than only rodent, data, a level of mechanistic human confirmation that most peptides in this queue lack entirely.

From a pharmacokinetic and regulatory standpoint, bremelanotide is given by subcutaneous injection via a single-use autoinjector, reaches peak plasma concentration in about an hour, and has a short elimination half-life of approximately 2.7 hours, consistent with its as-needed, single-occasion dosing pattern rather than continuous maintenance therapy. It is approved by the FDA specifically for hypoactive sexual desire disorder in premenopausal women, is manufactured under standard pharmaceutical quality control as a prescription medication, and its labeling specifies a maximum of one dose per 24 hours and eight doses per month, limits set based on the accumulated blood-pressure and hyperpigmentation safety data from its clinical development program. It is not approved for erectile dysfunction, for use in men, for use in postmenopausal women, or as a general aphrodisiac, and its efficacy and safety outside its approved population and dosing frequency have not been established by a completed pivotal trial. Because it produces a genuine, transient blood-pressure effect, it requires the same kind of prescriber oversight and contraindication screening as other cardiovascular-relevant medications, a regulatory posture distinct from the compounded, unregulated, or research-only status of most other peptides in this queue.

Mechanism of Action

Non-Selective Melanocortin Receptor Agonism

Bremelanotide is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone that binds and activates the melanocortin 1, 3, and 4 receptors (MC1R, MC3R, MC4R) without meaningful selectivity among them. This contrasts with several newer melanocortin-pathway peptides in development that pursue receptor-selective agonism specifically to separate a desired effect, such as appetite suppression through MC4R, from an unwanted one, such as pigmentation through MC1R. Because bremelanotide predates that selective-design approach, its clinical profile reflects the combined activity of all three receptors it engages, which explains why an approved drug for sexual desire also produces a documented, if uncommon, pigmentation side effect.

Central MC4R Activation and Sexual Desire Circuitry

The desire-enhancing effect of bremelanotide is attributed primarily to MC4R activation within hypothalamic regions implicated in sexual motivation, including the medial preoptic area and paraventricular nucleus, based on decades of rodent behavioral pharmacology using Melanotan II and related melanocortin agonists. A 2022 human functional MRI study extended this mechanistic picture into humans directly, finding that a single dose of bremelanotide altered activity in brain regions associated with sexual arousal processing and inhibitory control in women with hypoactive sexual desire disorder, evidence of a central nervous system site of action rather than a peripheral vascular one. This central mechanism is the primary reason bremelanotide is mechanistically distinct from phosphodiesterase-5 inhibitors, which act on vascular smooth muscle to increase genital blood flow rather than on brain circuits governing desire itself.

MC1R Activation and Focal Hyperpigmentation

Bremelanotide non-selective binding profile also activates MC1R on melanocytes, the same receptor Melanotan II was originally designed to exploit for cosmetic tanning. In the context of an approved desire-focused drug, this MC1R activity is an unwanted but mechanistically predictable consequence rather than a therapeutic target, and it accounts for the focal skin, gum, and breast hyperpigmentation observed in a small percentage of patients using approved dosing, particularly with more frequent use and in patients with darker skin.

MC3R Activation and Energy Homeostasis

Bremelanotide activity at MC3R, a melanocortin receptor also implicated in energy balance regulation, is proposed as the mechanistic link to a modest, incidentally observed reduction in body weight reported in a post hoc analysis of trial data in women with obesity. This effect was not the subject of a dedicated weight-management trial and bremelanotide carries no weight-loss indication, but the finding is consistent with the broader melanocortin pathway role in appetite and energy expenditure documented across other MC4R-targeting peptides.

Blood Pressure and Heart Rate Effects

Bremelanotide produces a small, transient increase in blood pressure and decrease in heart rate, peaking 2 to 4 hours after dosing and generally resolving within about 12 hours. The precise mechanism is not fully characterized in humans but is believed to involve central melanocortin pathway effects with downstream sympathetic nervous system involvement, distinct from a direct peripheral vasoconstrictive action. This effect, while modest in the trials supporting approval, is real and dose-related, and is the basis for bremelanotide contraindication in patients with uncontrolled hypertension or known cardiovascular disease.

Clinical Evidence

Pivotal Phase 3 Trial Program (RECONNECT)

The primary evidence supporting bremelanotide approval comes from two identical, multicenter, randomized, double-blind, placebo-controlled phase 3 trials, the RECONNECT studies, published in Obstetrics and Gynecology in 2019 and enrolling a combined 1,247 premenopausal women with acquired, generalized hypoactive sexual desire disorder. Self-administered subcutaneous bremelanotide at 1.75 milligrams, taken as needed before anticipated sexual activity, produced statistically significant improvement over placebo in both co-primary endpoints across the 24-week treatment period: an increase in Female Sexual Function Index desire-domain score and a reduction in desire-related distress. The trial design, using as-needed rather than scheduled dosing, reflects the intended real-world use pattern of the approved drug.

Dose-Ranging Trial and Responder Analysis

A preceding phase 2b, randomized, placebo-controlled dose-ranging trial established the 1.75-milligram dose carried forward into the phase 3 program. A 2019 published responder analysis of that trial found a higher proportion of women achieving a clinically meaningful improvement in desire or reduction in distress with bremelanotide than with placebo, but a substantial minority of placebo-treated women also met responder criteria, a pattern common across sexual-desire trials generally and part of why the treatment effect attributable specifically to bremelanotide, while statistically significant and the basis for regulatory approval, is described in the literature as modest in absolute magnitude.

Human Neuroimaging Mechanistic Evidence

A 2022 functional MRI study, published in the Journal of Clinical Investigation, found that a single dose of bremelanotide altered blood-oxygen-level-dependent activity in brain regions associated with sexual arousal processing and inhibitory control in women with hypoactive sexual desire disorder, compared with placebo. This is among the more direct pieces of human mechanistic evidence available for any peptide in this queue, corroborating decades of rodent behavioral pharmacology with a controlled human imaging study rather than relying on inference from animal models alone.

Long-Term Extension and Patient Experience

A long-term, open-label extension study following the RECONNECT trials characterized continued safety and patient-reported benefit of ongoing as-needed bremelanotide use over roughly a year. A separate 2021 exit-study analysis characterized real-world patterns of treatment continuation and discontinuation among women who had participated in the RECONNECT program, finding that tolerability issues, particularly nausea, were a common reason for stopping, alongside patients who continued to find meaningful value in as-needed use.

Safety and Tolerability

A 2022 pooled safety analysis across the full bremelanotide clinical development program found nausea in approximately 40 percent of patients overall, with the incidence sharply front-loaded to the first dose (approximately 21 percent) and falling to single digits with subsequent doses; about 8 percent of patients discontinued treatment specifically because of nausea. Flushing (approximately 20 percent), injection-site reactions (approximately 13 percent), and headache (approximately 11 percent) were also common. Blood pressure increased transiently by up to approximately 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours post-dose. Focal hyperpigmentation of the skin, gums, or breast tissue occurred in about 1 percent of patients receiving up to the approved maximum monthly dosing frequency, with resolution after discontinuation not confirmed in all cases.

The Discontinued Male Erectile Dysfunction Program

Before its repositioning toward female hypoactive sexual desire disorder, bremelanotide, then called PT-141, was developed as an intranasal treatment for erectile dysfunction in men. Early studies documented pro-erectile activity, but the program was discontinued in the mid-2000s after regulators raised concerns about dose-related increases in blood pressure at the doses required for reliable intranasal efficacy in that population. This is a documented case of a peptide clinical program being stopped specifically because of a cardiovascular safety signal identified during development, rather than for lack of any biological effect, and it is part of why the eventual female-focused, lower-dose subcutaneous formulation carries the specific blood-pressure monitoring and contraindication language it does today.

Regulatory Status

Bremelanotide, marketed as Vyleesi, is approved by the United States Food and Drug Administration, with initial approval granted in June 2019, specifically for acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is manufactured under standard pharmaceutical quality control as a prescription medication, with an FDA-approved labeling document specifying its dosing limits (one dose per 24 hours, eight doses per month), contraindications (uncontrolled hypertension, known cardiovascular disease), and monitoring considerations. It is one of only two FDA-approved medications for hypoactive sexual desire disorder and the only approved peptide-based option for that indication. Bremelanotide is not approved for erectile dysfunction, for use in men, for use in postmenopausal women, or as a general aphrodisiac, and using it outside its approved population or dosing frequency is off-label and unsupported by the trial evidence. It should also be distinguished clearly from unapproved Melanotan I and Melanotan II products sold for tanning outside medical supervision, which are related but separate compounds without bremelanotide regulatory oversight or trial-documented safety record.

Bremelanotide versus Flibanserin

Bremelanotide and flibanserin (Addyi) are the only two FDA-approved medications for hypoactive sexual desire disorder in premenopausal women, but they differ substantially in mechanism and use pattern. Flibanserin is a daily oral medication acting on serotonin and dopamine receptor systems, requires several weeks of continuous use before an effect is assessed, and carries a boxed warning about severe hypotension and syncope with alcohol use. Bremelanotide is an as-needed subcutaneous injection acting on melanocortin receptors, used only around anticipated sexual activity rather than daily, and its principal safety concerns are nausea and a transient blood-pressure increase rather than an alcohol-interaction-driven hypotension risk. Neither drug produces a large effect size over placebo in its pivotal trials, a shared characteristic reflecting the broader difficulty of demonstrating pharmacologic benefit for sexual desire, a state with substantial psychological and interpersonal contributors that a single molecular target is unlikely to fully address.

Dosing Guidance

The FDA-approved dosing regimen is 1.75 milligrams administered by subcutaneous injection using a single-use, prefilled autoinjector, self-administered into the abdomen or thigh approximately 45 minutes before anticipated sexual activity, as needed rather than on a fixed schedule. The maximum approved frequency is one dose per 24 hours and eight doses per month, limits established based on the blood-pressure and hyperpigmentation safety data accumulated across the clinical development program at that dosing pattern. No alternative dose, schedule, or route has been established as safe or effective in a completed pivotal trial; doses above 1.75 milligrams were characterized only in early pharmacokinetic studies and are not part of the approved regimen, with plasma exposure plateauing rather than increasing proportionally at higher doses.